Last reviewed · How we verify
Breath of Life International Pharma Ltd — Portfolio Competitive Intelligence Brief
6 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| A3 | A3 | marketed | Angiotensin receptor blocker | AT1 receptor | Cardiovascular | |
| A5 | A5 | marketed | SGLT2 inhibitor | SGLT2 | Diabetes | |
| B4 | B4 | marketed | monoamine oxidase inhibitor | monoamine oxidase A | Psychiatry | |
| A1 | A1 | marketed | SGLT2 inhibitor | SGLT2 | Diabetes | |
| A4 | A4 | marketed | CD4 receptor antagonist | CD4 | Infectious Disease | |
| A2 | A2 | marketed | Norepinephrine-dopamine reuptake inhibitor | Psychiatry |
Therapeutic area mix
- Diabetes · 2
- Psychiatry · 2
- Cardiovascular · 1
- Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Asan Medical Center · 2 shared drug classes
- Pfizer · 2 shared drug classes
- AJU Pharm Co., Ltd. · 1 shared drug class
- Abbott · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Aciex Therapeutics, Inc. · 1 shared drug class
- AO GENERIUM · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Breath of Life International Pharma Ltd:
- Breath of Life International Pharma Ltd pipeline updates — RSS
- Breath of Life International Pharma Ltd pipeline updates — Atom
- Breath of Life International Pharma Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Breath of Life International Pharma Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/breath-of-life-international-pharma-ltd. Accessed 2026-05-17.